Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.73 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.73 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.66 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6614812 | 0.90 | CYP4A11 (0.73) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL19078986 | 0.90 | CYP4A11 (0.78) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL70173 | 0.90 | CYP4F2 (0.83) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL19078992 | 0.89 | CYP4A11 (0.76) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL28212 | 0.86 | LOXL2 (0.70) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL29592260 | 0.86 | LOXL2 (0.70) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL10609527 | 0.85 | CYP4F2 (0.76) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL46931 | 0.85 | CYP4A11 (1.00) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL1696378 | 0.85 | CYP4F2 (0.76) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL28002924 | 0.85 | CYP4F2 (0.53) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4486453-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-116120261-B | Preparation method of 3- [ (4-sulfadiazine-1-yl) methyl ] benzoic acid compound | 浙大宁波理工学院 | 2024-01-23 | — | — | CN | disclosed |
| WO-2023166103-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| CN-116120261-A | Preparation method of 3- [ (4-sulfadiazine-1-yl) methyl ] benzoic acid compound | 浙大宁波理工学院 | 2023-05-16 | — | — | CN | disclosed |
| US-11358955-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20190270732-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS, INC. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-2709990-B1 | 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer | IMPACT THERAPEUTICS INC (CN) | 2019-06-12 | — | — | EP | disclosed |
| US-10316027-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | IMPACT THERAPEUTICS, INC. (CN) | 2019-06-11 | — | — | US | disclosed |
| CN-108976158-A | A kind of anti-AIDS Benzazole compounds and preparation method thereof and its application | 东莞理工学院 | 2018-12-11 | — | — | CN | disclosed |
| US-20180215741-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | IMPACT THERAPEUTICS INC (CN) | 2018-08-02 | — | — | US | disclosed |
| CN-1171400-A | Xantone compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-01-28 | — | — | CN | disclosed |
| EP-0817787-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| CN-1151735-A | Benzocycloalkylazolethione derivatives | SYNTEX INC (US) | 1997-06-11 | — | — | CN | disclosed |
| EP-0683781-A4 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE. | GENSIA PHARMA (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996030377-A1 | NITROGENOUS MACROCYCLIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| CN-1123545-A | Guanidine derivatives as inhibitors of Na+/H+ exchange in cells | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-05-29 | — | — | CN | disclosed |
| EP-0683781-A1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | GENSIA PHARMACEUTICALS, INC. (US) | 1995-11-29 | — | — | EP | disclosed |
| CN-1098715-A | PLA 2 inhibitors 1H-indole-3-acetamide compounds | LILLY CO ELI (US) | 1995-02-15 | — | — | CN | disclosed |
| CN-1095721-A | New compounds | SMITHKLINE BEECHAM PLC (GB) | 1994-11-30 | — | — | CN | disclosed |
| WO-1994018200-A1 | NOVEL INHIBITORS OF ADENOSINE MONOPHOSPHATE DEAMINASE | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270732-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | CYP4F2 3211/4885CYP4A11 1852/4885LOXL2 3855/4885 |
| US-10316027-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | PARP1, PARP11, PARP3 | CYP4F2 3415/4885CYP4A11 1827/4885LOXL2 3890/4885 |
| US-20180215741-A1 | 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof | PARP1, PARP11, PARP3 | CYP4F2 3415/4885CYP4A11 1827/4885LOXL2 3890/4885 |
| US-11358955-B2 | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | PARP1, PARP11, PARP3 | CYP4F2 3211/4885CYP4A11 1852/4885LOXL2 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.